Oral Session 3-8D Indolent lymphoma: Clinical studies

[OS3-8D-5] Bendamustine plus rituximab in the treatment of indolent lymphoma

Kyoko Yoshihara^1,7, Yoshifumi Shimizu^2,7, Hiroyuki Kawamoto^3,7, Hiroyuki Takatsuka^4,7, Tazuko Tokugawa^1,7, Akihiro Sawada^1,7, Satoshi Yoshihara^1,5,7, Masaya Okada^1,7, Mahito Misawa^6,7, Hidetaka Ifuku^4,7, Takahiro Okamoto^2,7, Yokiko Ooe^4,7, Yoshihiro Fujimori^1,5,7 (1.Hematology, Hyogo College of Medicine, Hyogo, Japan, 2.Hematology, Takarazuka City Hospital, Hyogo, Japan, 3.Hematology, Uegahara Hospital, Hyogo, Japan, 4.Hematology, Amagasaki Chuo Hospital, Hyogo, Japan, 5.Transfusion Medicine/Cellular Therapy, Hyogo College of Medicine, Japan, 6.Hematology, Ako Central Hospital, Hyogo, Japan, 7.Mukogawa Hematology Study Group, Hyogo, Japan)